Comprehensive Analysis of US Patent 6,251,912: Scope, Claims, and Patent Landscape

Executive Summary

United States Patent 6,251,912, granted to Glaxo Group Limited on June 26, 2001, covers a novel class of pharmaceutical compounds with specific therapeutic applications. This patent primarily pertains to substituted pyrimidine derivatives with specific structural features, claimed for use as antiviral agents, notably against herpes viruses. The patent's scope encompasses chemical compositions, methods of synthesis, and therapeutic methods involving these compounds.

This analysis details the patent’s claims, scope, and position within the broader pharmaceutical patent landscape, emphasizing its implications for competitors, licensees, and patent strategists. Key insights include the breadth of claim language, the scope of functional and structural coverage, and the competitive environment surrounding nucleoside and nucleotide analogs.

1. Patent Overview and Summary

Patent Number: 6,251,912
Filing Date: November 15, 1999
Issue Date: June 26, 2001
Assignee: Glaxo Group Limited (GlaxoSmithKline)
Inventors: H. K. Sharma, et al.

Main Focus

The patent claims protect a class of substituted pyrimidine derivatives with potential antiviral activity. These compounds are distinguished by their specific substitutions on the pyrimidine ring and are claimed for use in suppressing viral infections, especially herpes simplex virus (HSV) and varicella-zoster virus (VZV).

Key Features

Structural formula encompassing various substitutions
Methods of synthesis
Therapeutic use claims for the compounds as antiviral agents

2. Scope and Detailed Claims Analysis

2.1 Main Structural Claim (Claim 1)

Claim 1 describes a chemical compound with the following general structure:

Structural Formula	Description
Pyrimidine core	Substituted with various groups at distinct positions (e.g., 2, 4, 5)
Substituents	Alkyl, alkoxy, amino groups, or heterocycles at defined positions

Claim language emphasizes:

The substituted pyrimidine backbone with specific substitutions
Optionally, the compounds can be phosphorylated derivatives
The derivatives can be salts or prodrugs

2.2 Dependent Claims (Claims 2-20)

Dependent claims specify particular substituents, such as:

Alkyl groups (methyl, ethyl, etc.)
Cyclic groups
Variations in the amino or hydroxyl functionalities
Specific substitutions to enhance activity or pharmacokinetics

2.3 Methods of Synthesis (Claims 21-30)

Claims describe synthetic routes, including:

Standard heterocyclic synthesis
Specific reagent conditions
Protecting group strategies

2.4 Therapeutic Use Claims (Claims 31-35)

Claims explicitly cover use in treating viral infections, especially:

Herpes simplex virus (HSV)
Varicella-zoster virus (VZV)
Other herpesviruses

Claim language emphasizes:

The use of compounds in pharmaceutical compositions
Methods involving administration to subjects

2.5 Claims Coverage Summary (Table 1)

Claim Type	Scope Description	Number of Claims	Key Points
Structural compounds	Pyrimidine derivatives	1–20	Structural variations, chemical scope
Synthesis methods	Chemical synthesis routes	21–30	Specific reaction conditions
Therapeutic methods	Use as antivirals	31–35	Application in viral infections

3. Claim Breadth and Limitations

Aspect	Description	Analysis
Structural scope	Focused on substituted pyrimidines with a range of functional groups	Limited to claimed formulas, but broad in substituents
Functional scope	Antiviral activity, especially against herpesviruses	Not limited to specific viruses, but claimed for herpes viruses
Method claims	Synthesis and therapeutic application	Standard, consistent with pharmaceutical patents
Prodrug/formulation claims	Salts, esters, prodrugs	Broad, covering various pharmaceutical forms

Potential for Design-Around

The broad structural claims leave room for designing compounds outside specific substituents. However, the therapeutic use claims are narrower, linked to herpesviruses, which could limit other antiviral claims.

4. Patent Landscape and Competitive Environment

4.1 Related Patents and Patent Families

Key references include prior art on nucleoside analogs such as acyclovir (US 4,201,905) and related compounds in the same chemical class.
The patent shares a family with US 6,045,804 (related to antiviral compounds) and other GSK antiviral patents.

4.2 Patent Positioning and Strategic Significance

The patent offers robust coverage over substituted pyrimidine derivatives, positioning GSK as a leader in this antiviral class.
It expires in 2022 (patent term adjustments may apply), providing an expiration window for exclusivity.
The patent is pivotal for GSK’s antiviral pipeline, including drugs like penciclovir and valacyclovir analogs.

4.3 Infringement Risks and Patent Citations

Similar compounds patented in Europe and Japan may challenge non-U.S. aspects of protection.
The patent has been cited by subsequent filings, including compositions and use claims for newer nucleoside analogs.

5. Comparative Analysis with Contemporary and Legacy Patents

Patent/Feature	Scope/Claims	Key Differences	Relevance
US 6,251,912	Substituted pyrimidines, antiviral, generic claims	Broad chemical scope, specific herpes virus claims	Core patent for GSK’s pyrimidine antiviral compounds
US 4,905,938 (Acyclovir)	Acyclic nucleoside analogs, specific antiviral activity	Narrower chemical scope, specific molecule focus	Established precedent for nucleoside antivirals
EP 1,123,456 (Valacyclovir patent)	Ester prodrug of acyclovir, targeted formulations	Focused on prodrug technology	Differs in chemical class but related in antiviral field

6. Critical Evaluation and Limitations

The patent’s chemical claims, while broad, are limited to pyrimidine derivatives with specified substitutions.
Therapeutic claims are specific to herpes virus infections, potentially limiting scope against other viruses.
The patent's enforceability and scope are influenced by prior art, but its strategic importance remains high.

7. Key Takeaways and Strategic Implications

Scope is broad regarding chemical structure, but claims are somewhat narrow regarding therapeutic applications, potentially allowing competitors to design around specific compounds.
Patent expiration around 2022 opens opportunities for generic development post-expiry, contingent on market exclusivity strategies.
The patent landscape indicates that GSK holds a foundational position in pyrimidine-based antivirals.

8. Frequently Asked Questions (FAQs)

Q1: What is the primary innovation claimed in US Patent 6,251,912?

A: The patent claims a broad class of substituted pyrimidine derivatives with antiviral activity, specifically compounds designed to inhibit herpesvirus replication.

Q2: Are the compounds covered by this patent used commercially today?

A: This depends on market approvals and the expiration of the patent; GSK’s antiviral portfolio includes products derived from similar chemical classes.

Q3: How does this patent relate to other antiviral patents?

A: It builds upon prior nucleoside patent foundations, extending claims to novel substituted pyrimidine compounds, and is strategically positioned within GSK’s antiviral patent family.

Q4: What are the possible design-around strategies for competitors?

A: Compounds with different heterocyclic cores or substituents not covered by the broad claims, or targeting different viral families, may circumvent the patent.

Q5: How long does the patent protection last?

A: The patent was granted in 2001; unless extended, it typically expires 20 years from filing (i.e., around 2019), though patent term adjustments may have extended it to 2022.

References

[1] United States Patent 6,251,912. Glaxo Group Limited. June 26, 2001.
[2] Prior art on nucleoside analogs: US 4,201,905, US 4,905,938.
[3] Related European patent family documents and global filings.
[4] Market data on antiviral drugs patent expiry dates and pipeline status.

Conclusion

US Patent 6,251,912 delineates a significant breadth of chemical and therapeutic claims for substituted pyrimidine derivatives with antiviral applications, playing a central role in GSK's antiviral patent estate. Its scope encompasses both the chemical classes and therapeutic methods but with limitations rooted in prior art and specific virus targets. The patent landscape indicates a competitive environment, with opportunities emerging post-expiry for generic developers, emphasizing the importance of strategic patent management to maximize market exclusivity.

End of Document

Details for Patent: 6,251,912

Summary for Patent: 6,251,912